Atara Biotherapeutics (ATRA) Liabilities from Discontinued Operations (2022)

Atara Biotherapeutics (ATRA) posted Liabilities from Discontinued Operations of 252000.0 for Q1 2022.

Atara Biotherapeutics (ATRA) Liabilities from Discontinued Operations (2022) Analysis & Trends

Atara Biotherapeutics' Liabilities from Discontinued Operations history runs 1 years deep, the most recent figure standing at 252000.0 for Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Atara Biotherapeutics 110.04 Mn 101.68 Mn 392,000.00

Historic Data

Download Data
DateValue
Mar 31, 2022 252,000.00
Mar 31, 2022 252,000.00